# Sight Sciences to Present at Two Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/SGHT/sight-sciences-to-present-at-two-upcoming-investor-conferences
Ticker: SGHT
Company: Sight Sciences
Source: Sight Sciences
Published: 2026-04-29 20:05 EST
Original Source URL: https://investors.sightsciences.com
## Summary

MENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today

## Article Body
MENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today
## Recent Company News
- 2026-05-06 20:05 EST — [Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance](https://biopharmsignal.com/news/SGHT/sight-sciences-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-revenue-guidance) — Source: Sight Sciences
- 2026-04-29 20:05 EST — [Sight Sciences to Present at Two Upcoming Investor Conferences](https://biopharmsignal.com/news/SGHT/sight-sciences-to-present-at-two-upcoming-investor-conferences) — Source: Sight Sciences
- 2026-04-22 20:45 EST — [Sight Sciences Announces the Release of its Sustainability Report](https://biopharmsignal.com/news/SGHT/sight-sciences-announces-the-release-of-its-sustainability-report) — Source: Sight Sciences
- 2026-04-21 20:05 EST — [Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026](https://biopharmsignal.com/news/SGHT/sight-sciences-to-report-first-quarter-2026-financial-results-on-may-6-2026) — Source: Sight Sciences
- 2026-04-01 20:05 EST — [Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting](https://biopharmsignal.com/news/SGHT/sight-sciences-interventional-technologies-for-glaucoma-and-dry-eye-disease-to-be-featured-in-multiple-clinical-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-ascrs-annual-meeting) — Source: Sight Sciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)